Clinical Trials

Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India

Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.

NewAmsterdam Pharma completes $196m Series A funding for phase 3 development programme

NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, announced completion of a $196M (€160M) Series A funding round.

GSK, Vir Biotechnology to evaluate neutralising Covid-19 antibody in AGILE study

GlaxoSmithKline, along with Vir Biotechnology, has agreed with the UK-based AGILE initiative to assess VIR-7832 in patients with mild to moderate Covid-19 in a phase 1b/2a clinical study.

Russian Covid-19 vaccine Sputnik V succeeds in phase 2 trial in India

Dr. Reddy’s Laboratories said that the Russian Covid-19 vaccine Sputnik V has met the primary endpoint of safety in a phase 2 clinical trial in India.

Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia

Teva Pharmaceuticals Industries and MedinCell announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia.

AM-Pharma enrols first patients in Covid-19 phase III trial

AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.

MODAG initiates first-in-patient phase 1b trial for Anle138b in Parkinson´s Disease

MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).

Lilly to begin pragmatic study of bamlanivimab for COVID-19 in New Mexico

Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.

Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial

Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) and its secondary efficacy endpoint of objective response rate (ORR) in patients with advanced endometrial cancer following at least one prior platinum-based regimen.